Thursday, August 03, 2017 7:01:11 AM
benefits outweigh risks for SequestOx
FDA will approve SequestOx!
Catalysts for significant revenue growth and improvement of share price in the very near future!
1. SequestOxTM (ELI-200) Opioid
NDA Pending Approval
Benefits outweigh risks
http://m.ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=83707&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939
2. Oxycodone Hydrochloride ER with ADT
10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg Tablets
(Generic OxyContin ADT)
Pending ANDA submittal
Submittal this quarter
Positive, top line BE results press released on 1/17/17
http://m.ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=82907&GoTopage=2&Category=2163&BzID=2258&t=1948&G=939
3. Oxycodone Hydrochloride and Acetaminophen
USP 5 mg/325 mg, 7.5 mg/325 mg, 10 mg/325 mg Tablets
(Generic Percocet)
Pending approval
ANDA submitted on 8/10/2016
http://m.ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=82211&GoTopage=3&Category=2163&BzID=2258&t=1948&G=939
4. Hydrocodone Bitartrate and Acetaminophen, USP 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg Tablets
(Generic Norco)
Pending approval
ANDA submitted on 12/12/2016
http://m.ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=82799&GoTopage=2&Category=2163&BzID=2258&t=1948&G=939
5. Synthetic Narcotic Analgesic
(Undisclosed Generic)
Pending approval
ANDA submitted on 4/4/2017
http://m.ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=83245&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939
6. Undisclosed Generic
(Undisclosed Generic)
Positive, top line BE results press released on 5/30/17
Pending Approval
ANDA submitted on?
http://m.ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=83551&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939
7. Additional Approved ANDAs
*pending site transfer
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:15:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/29/2023 09:15:09 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/29/2023 08:43:45 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM